Impact News +++ Ant Group Elevates Health Care to Core Business in Major AI Push (Caixin) +++ JD HEALTH Aktie +3,10%

SOLENO Aktie

>SOLENO Aktienkurs

39.24 EUR +4.1% (Tradegate)

Ask: 40.5 EUR / 150 Stück

Bid: 40.02 EUR / 150 Stück

Tagesumsatz: 919 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

SOLENO Aktie über LYNX handeln

Intraday

1 Jahr

>SOLENO Performance

1 Woche: -40,1%

1 Monat: -27,2%

3 Monate: -46,3%

6 Monate: -42,7%

1 Jahr: -29,9%

laufendes Jahr: -12,9%

>SOLENO Aktie

Name:

SOLENO THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8342033094 / A3DS0P

Symbol/ Ticker:

6XC (Frankfurt) / SLNO (NASDAQ)

Kürzel:

FRA:6XC, ETR:6XC, 6XC:GR, NASDAQ:SLNO

Index:

Webseite:

https://soleno.life/

Profil:

Soleno Therapeutics Inc. is a biopharmaceutical co..
>Volltext..

Marktkapitalisierung:

2185.91 Mio. EUR

Unternehmenswert:

1806.42 Mio. EUR

Umsatz:

85.68 Mio. EUR

EBITDA:

-71.43 Mio. EUR

Nettogewinn:

-68.12 Mio. EUR

Gewinn je Aktie:

-1.59 EUR

Schulden:

45.73 Mio. EUR

Liquide Mittel:

214.18 Mio. EUR

Operativer Cashflow:

-22.54 Mio. EUR

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

43.25%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SOLENO

Letzte Datenerhebung:

07.11.25

>SOLENO Kennzahlen

Aktien/ Unternehmen:

Aktien: 53.71 Mio. St.

Frei handelbar: 86.58%

Leerverk. Aktien: 15.87%

Rückkaufquote: -9.71%

Mitarbeiter: 92

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 160.91%

Bewertung:

KGV: -

KGV lG: -

KUV: 28.44

KBV: 4.96

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 97.12%

Gewinnmarge: -79.5%

Operative Marge: -85.4%

Managementeffizenz:

Gesamtkaprendite: -17.5%

Eigenkaprendite: -20.66%

>SOLENO Peer Group

Es sind 597 Aktien bekannt.

>SOLENO Chart & Kurs - NASDAQ

>SOLENO News

07.11.25 - 16:06	Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman (PR Newswire)
	SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing information......

05.11.25 - 19:57	Soleno plunges despite Q3 beat as demand for Vykat XR cools (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 07:51	Soleno signals continued VYKAT XR market growth with net revenue doubling to $66M as European expansion advances (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.10.25 - 13:03	Soleno Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November:...

21.10.25 - 14:03

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET (GlobeNewswire EN)

REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations....

21.10.25 - 03:12	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

18.10.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

16.10.25 - 20:06	Soleno Therapeutics gains amind renewed takeover speculation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.10.25 - 02:03	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

13.10.25 - 20:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

13.10.25 - 14:03	Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors (GlobeNewswire EN)
	Appointment adds three decades of financial and operational leadership to Soleno's Board Appointment adds three decades of financial and operational leadership to Soleno's Board...

08.10.25 - 23:48	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

07.10.25 - 18:57	Soleno rated as new Buy at Goldman Sachs on Vykat XR potential (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.10.25 - 21:03	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Oct. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

03.10.25 - 16:01	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

01.10.25 - 00:49	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

25.09.25 - 01:45	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Sept. 24, 2025 Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued materially......

24.09.25 - 14:12	Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.09.25 - 14:03	Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO (PR Newswire)
	NEW YORK, Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued......

18.09.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO (PR Newswire)
	NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Bildung scheint mir das einzige Ziel, das des Bestrebens, Wahrheit der einzige Reichtum, der des Besitzes würdig ist. - Heinrich von Kleist

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram